IMS client work spans solid and liquid tumors, major and niche cancers, as well as supportive care. Our engagements in such areas as breast, lung, and cervical cancer, as well as renal cell carcinoma and chronic myelogeneous leukemia, have aided clients in building patient and indication strategies to maximize market access, health economic and outcomes research to ensure market reimbursement, and product positioning to drive market uptake.
- Countering competitor launches with optimal brand positioning in breast cancer
Assisting our client's brand team to prepare counter launch strategies against two new products for breast cancer likely to hit the market soon. - Ensuring market access for prostate drug
Supporting a client with a new adjuvant therapy for early prostate cancer face the need to generate economic support for the drug's anticipated budgetary impact after launch in a European market. - Explaining regional variances in cancer treatments
Analyzing unexplained and extreme regional differences in uptake in two very effective, but expensive cancer treatments. - Maximizing patient potential with perceptual modeling
Providing an in-depth picture of the way oncologists perceive current treatments in the CRC arena and calculating potential share in each of the patient segments identified. - Optimizing market share with multiple oncology regimens
Identifying the most appropriate positioning strategy for each of a client's regimens in the colorectal market, and providing a detailed understanding of the reasons behind prescribing choice. - Optimizing product positioning using sufficiency thresholds
Helping a client who had developed a new cytotoxic regimen for non-small cell lung cancer and was preparing for launch.
